Jeffrey M. Weinberg, MD; Lawrence F. Eichenfield, MD; Melinda Gooderham, MD, FRCPC
This activity is jointly provided by Global Education Group and Integritas Communications.
This activity is supported by an educational grant from Sanofi Genzyme and Regeneron Pharmaceuticals.
Jeffrey M. Weinberg, MD
Associate Clinical Professor of Dermatology
Harvard Medical School
Icahn School of Medicine at Mount Sinai
New York, New York
Director, Division of Dermatology
Jamaica Hospital Medical Center
Richmond Hill, New York
Lawrence F. Eichenfield, MD
Professor of Dermatology and Pediatrics
Vice Chair, Department of Dermatology
University of California, San Diego, School of Medicine
Chief, Pediatric and Adolescent Dermatology
Rady Children’s Hospital
San Diego, California
Melinda Gooderham, MD, FRCPC
Kingston, Ontario, Canada
SKiN Centre for Dermatology
Peterborough, Ontario, Canada
The educational design of this activity addresses the needs of dermatologists, allergists, and other clinicians who treat patients with moderate-to-severe atopic dermatitis.
Statement of Need/Program Overview
Atopic dermatitis is a chronic inflammatory condition with manifestations in the skin and in other organ systems throughout the body.1 Increasing in prevalence over the last 2 decades, the disease places tremendous burdens on patients, family members, and caregivers.1,2 The evolving understanding of disease pathophysiology and widespread effects on patient health and quality of life highlight the need for prompt diagnosis and proactive management.3,4 Moreover, research into the mechanisms underlying atopic dermatitis pathogenesis and progression has led to new approaches to disease characterization and treatment.5,6 This Interactive Exchange™ program will open with a brief 3D-animated video highlighting mechanistic insights into atopic dermatitis development. Expert faculty will then discuss best practices in comprehensive patient evaluations, and the clinical profiles, efficacy, and safety of treatment options for moderate-to-severe disease, including biologic therapy. With the overall goal of improving outcomes for patients with moderate-to-severe atopic dermatitis, the program will integrate clinical data and professional experience into actionable recommendations that can be used to individualize care and improve patient-clinician communication.
- Nutten S. Atopic dermatitis: global epidemiology and risk factors. Ann Nutr Metab. 2015:66(suppl 1):8-16.
- Drucker AM, et al. The burden of atopic dermatitis: summary of a report for the National Eczema Association. J Invest Dermatol. 2017;137(1):26-30.
- Eichenfield LF, et al. Guidelines of care for the management of atopic dermatitis: section 1. Diagnosis and assessment of atopic dermatitis. J Am Acad Dermatol. 2014;70(2):338-351.
- Sidbury R, et al. Guidelines of care for the management of atopic dermatitis: section 3. Management and treatment with phototherapy and systemic agents. J Am Acad Dermatol. 2014;71(2): 327-349.
- Ungar B, et al. An integrated model of atopic dermatitis biomarkers highlights the systemic nature of the disease. J Invest Dermatol. 2017;137(3):603-613.
- Simpson EL, et al. Two phase 3 trials of dupilumab versus placebo in atopic dermatitis. N Engl J Med. 2016;375(24):2335-2348.
After completing this activity, the participant will be better able to:
- Discuss pathophysiologic mechanisms and risk factors that contribute to atopic dermatitis development and persistence, including potential treatment targets
- Evaluate patients with atopic dermatitis over time for persistent symptoms, comorbidities, and treatment responses
- Describe the clinical profiles of current and emerging biologic therapies for moderate-to-severe atopic dermatitis
- Tailor long-term therapy for moderate-to-severe atopic dermatitis to prevent exacerbations, maximize health-related quality of life, manage comorbidities, and minimize adverse events
- Educate patients and caregivers to improve their understanding of atopic dermatitis, provide Action Plans to reduce exacerbations, and promote shared decision-making
Physician Accreditation Statement
This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of Global Education Group (Global) and Integritas Communications. Global is accredited by the ACCME to provide continuing medical education for physicians.
Physician Credit Designation
Global Education Group designates this enduring material for a maximum of 1.0 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Instructions to Receive Credit
In order to receive credit for this activity, the participant must score 70% or better on the posttest and complete the program evaluation
Microsoft Windows 2000 SE or above.
Flash Player Plugin (v184.108.40.206 or greater)
Internet Explorer (v5.5 or greater), or Firefox
Adobe Acrobat Reader*
MAC OS 10.2.8
Flash Player Plugin (v220.127.116.11 or greater)
Adobe Acrobat Reader*
Internet Explorer is not supported on the Macintosh.
Fee Information & Refund/Cancellation Policy
There is no fee for this educational activity.
Global Contact Information
For information about the accreditation of this program, please contact Global at 303-395-1782 or firstname.lastname@example.org
Disclosure of Conflicts of Interest
Global Education Group (Global) requires instructors, planners, managers, and other individuals and their spouses/life partners who are in a position to control the content of this activity to disclose any real or apparent conflict of interest they may have as related to the content of this activity. All identified conflicts of interest are thoroughly vetted by Global for fair balance, scientific objectivity of studies mentioned in the materials or used as the basis for content, and appropriateness of patient care recommendations.
The faculty reported the following financial relationships or relationships to products or devices they or their spouses/life partners have with commercial interests related to the content of this CME activity:
Jeffrey M. Weinberg, MD Grant/Research Support: Regeneron Pharmaceuticals, Inc.
Lawrence F. Eichenfield, MD Consultant/Independent Contractor: Anacor Pharmaceuticals, Inc.; Eli Lilly and Company; Genentech, Inc.; Medimetriks Pharmaceuticals, Inc.; Otsuka America Pharmaceutical, Inc.; Pfizer Inc.; Regeneron Pharmaceuticals, Inc.; sanofi-aventis U.S. LLC.; Top MD, Inc.; Valeant Pharmaceuticals International, Inc. Grant/Research Support: Regeneron Pharmaceuticals, Inc.; sanofi-aventis U.S. LLC.
Melinda Gooderham, MD, FRCPC Consultant/Independent Contractor: Akros Pharma Inc.; Boehringer Ingelheim International GmbH; Eli Lilly and Company; Janssen Inc.; Kyowa Hakko Kirin Co., Ltd.; Grant/Research Support: AbbVie Inc.; Akros Pharma Inc.; Amgen Inc; Boehringer Ingelheim International GmbH; Bristol-Myers Squibb Company; Celgene Corporation; Dermira, Inc.; Galderma SA; Janssen Inc.; Kyowa Hakko Kirin Co., Ltd.; LEO Pharma A/S; Novartis Pharmaceuticals Corporation; Regeneron Pharmaceuticals, Inc.; Roche Laboratories, Inc.; UCB, Inc.; Honoraria: AbbVie Inc.; Amgen Inc.; Boehringer Ingelheim International GmbH; Celgene Corporation; Eli Lilly and Company; Galderma SA; Janssen Inc.; LEO Pharma A/S; MedImmune, LLC; Novartis Pharmaceuticals Corporation; Pfizer Inc.; Regeneron Pharmaceuticals, Inc.; Sanofi Canada; Valeant Pharmaceuticals International, Inc.; Speakers Bureau: AbbVie Inc.; Actelion Pharmaceuticals US, Inc.; Amgen Inc.; Eli Lilly and Company; Galderma SA; Janssen Inc.; LEO Pharma A/S; Novartis Pharmaceuticals Corporation; Sanofi Canada; Valeant Pharmaceuticals International, Inc.
The following planners and managers reported the following financial relationships or relationships to products or devices they or their spouses/life partners have with commercial interests related to the content of this CME activity:
Ashley Marostica, RN, MSN Nothing to disclose
Andrea Funk Nothing to disclose
Jim Kappler, PhD Nothing to disclose
Rose O'Connor, PhD Nothing to disclose
Disclosure of Unlabeled Use
This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. Global Education Group (Global) and Integritas Communications do not recommend the use of any agent outside of the labeled indications.
The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of any organization associated with this activity. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.
Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed in this activity should not be used by clinicians without evaluation of patient conditions and possible contraindications on dangers in use, review of any applicable manufacturer’s product information, and comparison with recommend